Amgen's Supreme Court bid answered in long-running Repatha patent feud against Sanofi, Regeneron

The Supreme Court will let Amgen argue to resurrect a pair of Repatha patents that were put on ice back in 2019. At the time, a Delaware judge sided with Sanofi and Regeneron Pharmaceuticals after a series of Amgen wins in the long-running PCSK9 feud. The U.S. Court of Appeals upheld the lower court’s decision in 2021.